Chew A-L, Bennett A, Smith C H, Barker J, Kirkham B
Skin Therapy Research Unit, St John's Institute of Dermatology, Guy's, King's and St Thomas' School of Medicine, St Thomas' Hospital, London SE1 7EH, UK.
Br J Dermatol. 2004 Aug;151(2):492-6. doi: 10.1111/j.1365-2133.2004.06105.x.
Adalimumab, a fully human-derived recombinant monoclonal antibody against tumour necrosis factor-alpha, has been shown to be effective for the treatment of patients with moderately to severely active rheumatoid arthritis. We report two patients with long-standing recalcitrant psoriasis and psoriatic arthritis who, after multiple treatment failures with conventional and experimental antipsoriatic medications, both responded to treatment with adalimumab. Significant clinical improvement was noted in both skin and joint disease in the two patients after several weeks of treatment with adalimumab. We are unaware of previous published reports of adalimumab therapy in patients with psoriasis and psoriatic arthritis.
阿达木单抗是一种完全人源化的抗肿瘤坏死因子-α重组单克隆抗体，已被证明对治疗中度至重度活动性类风湿性关节炎患者有效。我们报告了两名患有长期顽固性银屑病和银屑病关节炎的患者，他们在使用传统和实验性抗银屑病药物多次治疗失败后，均对阿达木单抗治疗有反应。在使用阿达木单抗治疗几周后，两名患者的皮肤和关节疾病均有显著临床改善。我们未发现先前有关于阿达木单抗治疗银屑病和银屑病关节炎患者的报道。
